Curacle Co Ltd - ESG Rating & Company Profile powered by AI
The analysis of Curacle Co Ltd incorporates data points from across the web as well as from available disclosures by Curacle Co Ltd. The Disclosure score covers seventeen UN SDGs including: 'Zero Hunger', 'Responsible Production & Consumption' and 'Life below Water'. Scroll down to the end of this page for potential risks for Curacle Co Ltd based on sector, location and marketcap.
Curacle Co Ltd in the Biotechnology & Medical Research industry gained a UN SDG ESG Transparency Score of 3.0; made up of an environmental score of 1.6, social score of 4.8 and governance score of 2.7.
3.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Analytik Jena AG | 8.0 | High |
| 1 | Adagio Therapeutics Inc | 8.0 | High |
| ... | ... | ... | |
| 136 | Polski Bank Komorek Macierzystych SA | 3.1 | Medium |
| 136 | PolyPid Ltd | 3.1 | Medium |
| 140 | Curacle Co Ltd | 3.0 | Medium |
| 140 | Applied BioCode Corp | 3.0 | Medium |
| 140 | ChunLab Inc | 3.0 | Medium |
| ... | ... | ... | |
| 233 | XLR Medical Corp | 0.0 | Low |
| 233 | rEVO Biologics Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Curacle Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Curacle Co Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Curacle Co Ltd report the average age of the workforce?
Sign up for free to unlockDoes Curacle Co Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Curacle Co Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Curacle Co Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Curacle Co Ltd offer flexible work?
Sign up for free to unlockDoes Curacle Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Curacle Co Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Curacle Co Ltd conduct supply chain audits?
Sign up for free to unlockDoes Curacle Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Curacle Co Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Curacle Co Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Curacle Co Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Curacle Co Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Curacle Co Ltd disclose water use targets?
Sign up for free to unlockDoes Curacle Co Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Curacle Co Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Curacle Co Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Curacle Co Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Curacle Co Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Curacle Co Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Curacle Co Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Curacle Co Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Curacle Co Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Curacle Co Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Curacle Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Curacle Co Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Curacle Co Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Curacle Co Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Curacle Co Ltd disclose its waste policy?
Sign up for free to unlockDoes Curacle Co Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Curacle Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Curacle Co Ltd disclose energy use targets?
Sign up for free to unlockDoes Curacle Co Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Curacle Co Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Curacle Co Ltd
These potential risks are based on the size, segment and geographies of the company.
Curacle Co., Ltd., a bio-venture business, engages in the research and development of drugs for diseases caused by aging process and damage to blood vessels. Its products cover age-related vascular diseases, intractable metabolic diseases, and cancer targeting/immunotherapy. The company's products in pipeline include CU06, which covers treatment and medical indications, such as diabetic macular edema/retinopathy, acute respiratory distress syndrome, myocardial infarction, stroke treatment, concomitantly used with immunotherapy, inflammatory bowel disease treatment, and hereditary angioedema; CU03, which is in Phase 2a clinical trial study for the treatment of age-related macular degeneration; and CU01, a diabetic nephropathy medicine that completed Phase 2a clinical trial. Its products in back-up pipeline include CU02, a product for nonalcoholic steatohepatitis treatment; CU04, a product for the treatment of cancer (c-Myc inhibitor); and CU05, a product for the treatment of cancer (Amigo2-PDK1 inhibitor). The company was founded in 2016 and is based in Seongnam, South Korea.